Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has been drawing attention after a period of solid share price gains. This is prompting investors to reassess how its current ...
AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.
The AstraZeneca share price has risen to all-time highs over the past 12 months. Dr James Fox wishes he had more of the British pharma giant. The post Prediction: analysts think the AstraZeneca share ...
Key Insights Using the 2 Stage Free Cash Flow to Equity, AstraZeneca fair value estimate is UK£250 AstraZeneca's ...
InvestorsHub on MSN
AstraZeneca plans NYSE move, ending Nasdaq ADS listing to simplify US share trading
AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its ...
Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New ...
Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...
Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results